-
EHDN 2026 Part 1: What’s next in the Huntington’s disease treatment pipeline?
9 min read
Latest News
-
Skyhawk’s drug trial takes flight in the US
4 min read
Skyhawk’s FALCON-HD trial has dosed the first participants in the US with the drug, SKY-0515. The once-daily pill targets two drivers of HD, but does it actually slow disease? That’s the big question this study hopes to answer.
-
Mapping the neighborhood: huntingtin's new protein partners
7 min read
Study of huntingtin protein's 'neighbors' reveals dozens of new drug development targets
-
Does the HD mutation affect children's growth?
6 min read
A small study suggests kids with the HD mutation but no symptoms have subtle differences in growth. What does it mean
-
'Induced' stem cells make exciting advances
8 min read
Stem cells from HD patients: becoming important tools for researchers – and now correcting the HD mutation in the lab
-
ASO gene silencing reaches further, lasts longer
7 min read
Silencing the Huntingtin gene using ASO drugs reaches further, lasts longer and is safe. Human trial soon?
-
Phosphodiesterase inhibitors: new HD drugs entering trials soon
6 min read
CHDI and Pfizer announce exciting animal work and plans for a human trial with a drug targeting 'phosphodiesterases'.
-
Interview: CHDI's scientific team
8 min read
HDBuzz interviews the top scientists from CHDI, the largest funder of Huntington's disease research in the world.
-
Exercise increases cellular recycling
5 min read
Exercise boosts cellular recycling in mice. Could this be why exercise is also good for HD – or even help develop dru
-
The HDBuzz Prize for young science writers
3 min read
Announcing the HDBuzz Prize for young science writers!
-
What's the connection between Huntington's Disease and cancer?
6 min read
HD patients are less likely to get cancer, according to a study from Sweden – what does this mean?
-
Closing the care gap: new guidelines for HD care
6 min read
Closing the care gap: new guidelines to help every Huntington's disease patient get great care
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
